In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on GT Biopharma (GTBP – Research Report), with a price target of $25.00. The company’s shares closed last Tuesday at $10.72.
According to TipRanks.com, Burns is a 2-star analyst with an average return of 1.3% and a 31.9% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Black Diamond Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for GT Biopharma with a $25.50 average price target.
GT Biopharma’s market cap is currently $226.5M and has a P/E ratio of -1.40. The company has a Price to Book ratio of 9.84.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GT Biopharma, Inc. is engages in the development and commercialization of novel immuno-oncology products. Its products include OXS-1550, OXS-1650, OXS-3550, OXS-4550, OXS-1750, OXS-1950, and OXS-2050. The company was founded in 1965 and is headquartered in Westlake Village, CA.